glp 1 obesity GLP-1 Market Optimizing GLP-1 therapies for obesity

For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80

Ramsey, T

RC: Talk with your healthcare provider before stopping the medication, as there may be more affordable options available

Considerations for Women, Including PCOS For many women, weight management is deeply connected to hormonal health

Ahechu, P

Diabetes mellitus (DM) significantly increases the risk of cardiovascular diseases and the overall and cardiovascular mortality, and it is a pro-atherogenic factor that induces atherosclerosis development and/or accelerates its progression through a multifactorial process